Risk Communication with Patients

  • Hirose M
N/ACitations
Citations of this article
6Readers
Mendeley users who have this article in their library.

Abstract

Recently, the Ministry of Health, Labour and Welfare has made efforts toward the strengthening of dissemination of appropriate drug and safety information through information service for healthcare professionals. Furthermore, Pharmaceuticals and Medical Devices Agency (PMDA) enforced webpages regarding drug safety information tools, such as PMDA "MediNavi". In European Medicines Agency (EMA), during the preparation of information (such as patient leaflets), the Agency interacts and cooperates with patients' and consumers' organizations to ensure that it is adequately formulated and comprehensible to the target audience. To disseminate information that is of real good service to patients, further risk communication with patients (patient involvement) is expected.

Cite

CITATION STYLE

APA

Hirose, M. (2012). Risk Communication with Patients. YAKUGAKU ZASSHI, 132(5), 561–562. https://doi.org/10.1248/yakushi.132.561

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free